Abstract: A method for producing a model animal which has a desired lifetime, and in which a predetermined biological reaction can be induced, and a model animal are provided. The present invention produces a first individual in which a gene of interest is heterozygously deficient using a first ES cell from a non-human mammalian animal. Meanwhile, a fragment containing a homologous gene that has homology to the gene of interest is made, a second ES cell constituted so that a predetermined region on X chromosome of the animal can be substituted is used, and the fragment is introduced into the second ES cell to generate a substituted ES cell in which the predetermined region has been substituted with the fragment. A second individual is produced using the substituted ES cell. The first individual and the second individual are mated with each other to produce a model animal.

Abstract: The present invention provides a non-human mammalian animal model for type 2 diabetes, which spontaneously develops a pathological condition similar to human type 2 diabetes of a non-obese type seen in some Japanese people. The non-human mammalian animal model for type 2 diabetes according to the present invention is deficient in a Cdkal1 gene function on the chromosome of the ? cell of the pancreas.

Abstract: A purpose of the present invention is to provide a small chemical compound which especially promotes induction of the differentiation of ES cells into insulin-producing cells. Another purpose of the present invention is to provide: a method for inducing the differentiation of ES cells into insulin-producing cells using the compound; and an agent for promoting induction of the differentiation into insulin-producing cells. Another purpose of the present invention is to provide the thus-induced insulin-producing cells. Provided are: an agent for promoting induction of the differentiation of stem cells derived from a mammal into insulin-producing cells, which contains a compound that is selected from the group consisting of dopamine metabolism inhibitors, serotonin metabolism inhibitors, acetylchotine, acetylcholine degrading enzyme inhibitors and acetylcholine receptor activators; and a method for inducing differentiation using the agent for promoting induction of differentiation.

Abstract: It is an object of the present invention to provide a method for producing pluripotent cells that are free of the risk of cellular canceration and that can be applied to regenerative medicine with a high degree of safety. The present invention provides a method for producing pluripotent cells from somatic cells comprising a step of bringing bacteria having fermentation ability or a component or secretory product thereof into contact with somatic cells.

Abstract: A functional image creating method and a functional image creating apparatus, each enabling rendering of an activated region, are provided. A phase difference image PDr(x) is created using a complex image ?r(x) created from an MR signal in an inactive state and a complex image ??r(x) obtained by filtering the complex image ?r(x). A phase difference image PDa(x) is created using a complex image ?a(x) created from an MR signal in an active state and a complex image ??a(x) obtained by filtering the complex image ?a(x). Function signal images diff1(x) and diff2(x) are created using the phase difference images PDr(x) and PDa(x), respectively. A magnitude image Mr(x), a magnitude image Ma(x), a standard image, or a morphological image I(x) is masked with the function signal image diff1(x) or diff2(x), thereby a function image I?(x) with an activated region rendered is created.

Abstract: A flexible conductive material and a cable using the same, being resistant to one million times or more of dynamic driving and particularly suitable for wiring robots or automobiles. An average crystal grain size of crystal grains 20 forming a metal texture of a base material is 2 ?m or less, in which the crystal grains 20 being 1 ?tm or less are included at least 20% or more in a cross sectional ratio. Also, it is preferable to include 0.1 mass % to 20 mass % of nanoparticles 22.

Abstract: The present invention provides an agent for neurological disease, the agent comprising lipoprotein containing apolipoprotein E as the active substance thereof, in which a neuroprotective system via activation of neuroprotective molecules and/or the inactivation of neurodegeneration-inducing molecules, mediated by lipoprotein receptors, may work as a mechanism, and a prophylactic and therapeutic method for neurological diseases. The lipoproteins containing apolipoprotein E and/or neuroprotective system through, as the action mechanism, the activation of neuroprotective molecules and the inactivation of neurodegeneration-inducing molecules that are mediated by lipoprotein receptors have prophylactic and therapeutic effects of, including, inhibiting nerve cell apoptosis, on neurological disease such as various neurodegenerative diseases accompanied by nerve cell apoptosis as the essential condition.

Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described.

Abstract: The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies: (a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and (b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).

Abstract: A sulfur trioxide decomposition catalyst, in particular, a sulfur trioxide decomposition catalyst capable of lowering the temperature required when producing hydrogen by an S—I cycle process is disclosed. A sulfur trioxide decomposition catalyst that includes a composite oxide of tungsten, vanadium and at least one metal selected from the group consisting of transition metal and rare earth elements is provided. Also, a sulfur dioxide production process that includes decomposing sulfur trioxide into sulfur dioxide and oxygen by using the sulfur trioxide decomposition catalyst above is provided. Furthermore, a hydrogen production process, wherein the reaction of decomposing sulfur trioxide into sulfur dioxide and oxygen by an S—I cycle process is performed by the above-described sulfur dioxide production process is provided.

Abstract: An acoustic signal processing device includes a frequency domain transform unit configured to transform an acoustic signal to a frequency domain signal for each channel, a filter coefficient calculation unit configured to calculate at least two sets of filter coefficients of a filter for each section having a predefined number of frames with respect to a sampled signal obtained by sampling the frequency domain signal transformed by the frequency domain transform unit for each frame such that the magnitude of a residual calculated based on a filter compensating for the difference in transfer characteristics between the channels of the acoustic signal is minimized, and an output signal calculation unit configured to calculate an output signal of a frequency domain based on the frequency domain signal transformed by the frequency domain transform unit and at least two sets of filter coefficients calculated by the filter coefficient calculation unit.

Abstract: It is an object of the present invention to provide a novel mitochondrial function-improving agent and a novel PGC-1? expression inducing agent. The present invention provides a mitochondrial function-improving agent and a PGC-1? expression inducing agent each of which comprises a lysine-specific demethylase-1 (LSD-1) inhibitor.

Abstract: An objective is to provide screening methods for substances having an activity of promoting maturation into hemocytes. It was revealed that in the maturation process of erythrocytes and platelets, RP S19 multimers are released to the outside of the cell and act on the C5a receptors of erythroblasts and megakaryocytes, thereby causing maturation of erythroblasts and megakaryocytes to erythrocytes and platelets. Based on such findings, the present invention provides methods of screening for substances having an activity of promoting maturation into hemocytes by targeting the RP S19 multimers and C5a receptors. The screening methods of the present invention can detect hemocyte maturation using an increase of the R4 RGS family as an indicator. Furthermore, the present invention provides agents for promoting hemocyte maturation, which comprise RP S19 multimers and a substance having an activity of promoting maturation into hemocytes as useful components.

Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Abstract: The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.

Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Methods of using the disclosed compounds for treating patients infected with HIV are also described.

Abstract: A method of producing a Group II-VI compound semiconductor. The method involves generating a pulsed electrical discharge plasma between metallic electrodes in sulfur to produce a Group II-VI compound semiconductor. A method of producing a Group II-VI compound semiconductor phosphor using a pulsed electrical discharge plasma. A hexagonal crystal of Group II-VI compound semiconductor composed of a plurality of twin crystals.

Abstract: It is an object of the present invention to provide a method for producing a cell medicine that is effective for diseases while causing a low risk to these diseases. The present invention provides a method for producing a phagocyte that expresses a foreign protein, which comprises: a step of introducing a protein expression vector into an induced pluripotent stem cell; and a step of inducing the induced pluripotent stem cell, into which the protein expression vector has been introduced, to differentiate into a phagocyte.

Abstract: A method of treating food capable of easily softening or pulverizing food in a short time without losing nutrients is provided. A shock wave (SW) generated in a shock wave source is applied to food such as an apple or tea leaves to soften or pulverize the food. A large mechanical load is not necessary, so the food is easily softened or pulverized. Moreover, it is not necessary to heat the food, so the food is softened or pulverized in a short time without losing nutrients in the food due to heat during heating.